Novartis taps Harvard tech to advance cancer immunotherapy efforts – BioPharma Dive
Harvard School of Engineering and Applied Sciences |
Novartis taps Harvard tech to advance cancer immunotherapy efforts
BioPharma Dive Swiss pharma Novartis AG is teaming up with researchers from the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS), the Wyss Institute and the Dana-Farber Institute on a project to further develop the academic group's … Novartis, Harvard, Dana-Farber Partner on Biomaterial for Cancer Immunotherapies Harvard bioengineers' biomaterial-based cancer immunotherapies to be developed by Novartis SEAS-developed cancer immunotherapies to be commercialized by … |
